---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-23-000065"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:30:38.581713+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics 2023 annual meeting: auditor ratified, reverse stock split not approved

## Summary
- Ratification of CohnReznick LLP as independent auditor for FY2023 approved with 9,827,096 for, 232,432 against, 109,961 abstentions.
- Proposal to amend charter for reverse stock split (1:2 to 1:50) failed: 7,809,550 for, 2,326,090 against, 33,849 abstentions, not reaching majority of outstanding shares.
- Quorum of 63.69% (10,169,489 shares) present at May 31, 2023 annual meeting.

## SEC filing metadata
- accession: 0001842952-23-000065
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000065/0001842952-23-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000065/cntx-20230531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-23-000065
- JSON: https://secwatch.observer/filing/0001842952-23-000065.json
- Plain text: https://secwatch.observer/filing/0001842952-23-000065.txt

## Key facts
- Shareholder Votes
  Context Therapeutics Inc. shareholders approved Ratification of CohnReznick LLP as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: Proposal 1. To ratify the selection by the Audit Committee of the Board of Directors of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000065/0001842952-23-000065-index.htm
- Shareholder Votes
  Context Therapeutics Inc. shareholders rejected Amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio ranging from 1-for-2 to 1-for-50 at the 2023-05-31 meeting.
  - Proposal: reverse split
  - Outcome: failed
  - Meeting: 2023-05-31
  source text: Proposal 2. To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of its outstanding common stock at a reverse stock split ratio ranging from any whole number between 1-for-2 and 1-for-50, subject to and as determined by the Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000065/0001842952-23-000065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.